Anavex Life Sciences Corp (AVXL)

[bas2020]

Let's say a study compared two doses and placebo but the high dose was found to have many dropouts due to toxicity. It would be reasonable for the independent data monitoring committee to pass this info on to the company. They then would likely drop the high dose (and move all high dose patients to the lower dose) and continue the study, and possibly increase the numbers to be enrolled in the now only dose and the placebo.

In A2-73's case, higher dose (i.e. blood concentration) has shown to be more efficacious, which makes this drug much more promising.